Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Erleada (apalutamide)
i
Other names:
JNJ-56021927, ARN-509, ARN509, JNJ 56021927, JNJ927, JNJ 927, ARN 509, JNJ56021927, JNJ-927
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(9)
News
Trials
Company:
J&J
Drug class:
Androgen receptor antagonist
Related drugs:
‹
nilutamide (4)
GT0918 (3)
BMS-641988 (2)
bicalutamide implant (2)
EPI-7386 (2)
HC-1119 (1)
TAK 700 (1)
IONIS-AR-2.5Rx (0)
sulforafan alfadex (0)
TAS3681 (0)
TQB3720 (0)
TRC253 (0)
cyproterone acetate (0)
TOK-001 (0)
EPI-506 (0)
INO-464 (0)
nilutamide (4)
GT0918 (3)
BMS-641988 (2)
bicalutamide implant (2)
EPI-7386 (2)
HC-1119 (1)
TAK 700 (1)
IONIS-AR-2.5Rx (0)
sulforafan alfadex (0)
TAS3681 (0)
TQB3720 (0)
TRC253 (0)
cyproterone acetate (0)
TOK-001 (0)
EPI-506 (0)
INO-464 (0)
›
Associations
(9)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval
apalutamide
Sensitive
:
A1
apalutamide
Sensitive: A1 - Approval
apalutamide
Sensitive
:
A1
AR F877L
Prostate Cancer
AR F877L
Prostate Cancer
apalutamide
Resistant: C3 – Early Trials
apalutamide
Resistant
:
C3
apalutamide
Resistant: C3 – Early Trials
apalutamide
Resistant
:
C3
AR T878A
Prostate Cancer
AR T878A
Prostate Cancer
apalutamide
Resistant: C3 – Early Trials
apalutamide
Resistant
:
C3
apalutamide
Resistant: C3 – Early Trials
apalutamide
Resistant
:
C3
PTEN expression
Prostate Cancer
PTEN expression
Prostate Cancer
leuprolide acetate + apalutamide
Sensitive: C3 – Early Trials
leuprolide acetate + apalutamide
Sensitive
:
C3
leuprolide acetate + apalutamide
Sensitive: C3 – Early Trials
leuprolide acetate + apalutamide
Sensitive
:
C3
PTEN deletion
Prostate Cancer
PTEN deletion
Prostate Cancer
apalutamide
Sensitive: C3 – Early Trials
apalutamide
Sensitive
:
C3
apalutamide
Sensitive: C3 – Early Trials
apalutamide
Sensitive
:
C3
SPOP mutation
Prostate Cancer
SPOP mutation
Prostate Cancer
enzalutamide capsule + abiraterone acetate + apalutamide
Sensitive: C3 – Early Trials
enzalutamide capsule + abiraterone acetate + apalutamide
Sensitive
:
C3
enzalutamide capsule + abiraterone acetate + apalutamide
Sensitive: C3 – Early Trials
enzalutamide capsule + abiraterone acetate + apalutamide
Sensitive
:
C3
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
apalutamide
Sensitive: D – Preclinical
apalutamide
Sensitive
:
D
apalutamide
Sensitive: D – Preclinical
apalutamide
Sensitive
:
D
AR positive
Triple Negative Breast Cancer
AR positive
Triple Negative Breast Cancer
apalutamide
Sensitive: D – Preclinical
apalutamide
Sensitive
:
D
apalutamide
Sensitive: D – Preclinical
apalutamide
Sensitive
:
D
PTEN deletion
Prostate Cancer
PTEN deletion
Prostate Cancer
apalutamide + AZD4635
Sensitive: D – Preclinical
apalutamide + AZD4635
Sensitive
:
D
apalutamide + AZD4635
Sensitive: D – Preclinical
apalutamide + AZD4635
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login